UCB's Global Corporate Website

UCB successfully navigated the challenges of 2022 and is now set for an exciting launch year

Posted by
Sandrine Dufour, EVP Chief Financial Officer
22-Feb-2023


At UCB, we strongly believe that everyone deserves to live the best life they can. We understand the significant challenges that individuals face when confronted with health conditions, and it is for this reason that we draw inspiration from patients to drive innovation and scientific discovery. Through a collaborative approach with our employees and partners we provide sustainable long-term solutions and are able to launch innovative products that benefit many. It is this focus, care and forward thinking that fueled our growth in the last 90 years. And we are excited and ready to deliver more this year and in the years to come.

Just have a look at our full-year financial results of 2022 that we share with you today. With a 5.52 billion revenue, an underlying profitability of 1.26 billion and net raise of dividend per share of 2%, we have delivered results at the upper end of the guided range of revenues and EBITDA margins. This is a demonstration of our strength to overcome both external challenges such as the economic impact of the war in Ukraine, and inflation, but also internal such as the patent loss of 2 key medicines. It shows the strength of our patient-value strategy and resilience of our core products. And it proves that UCB is able to discover, develop and put on the market medicines that deliver unique, differentiated outcomes to patients all around the world. A true testament to our strategic thinking.

In 2022 we reached more than 3.4 million people living with severe immunological and neurological diseases. We are continually innovating and striving to find new ways to deliver solutions to these people to live their best possible lives. We hope to launch multiple new treatment options in 2023, paving the way for future growth. These treatments will support the battle against rare forms of epilepsy, myasthenia gravis, dermatological and rheumatological diseases.

Furthermore, we continued to develop our clinical pipeline, which now encompasses 9 clinical development medicines with our R&D ratio increasing to 30%. It shows our commitment to continue to invest in order to advance our clinical development pipeline and bring these medicines to people living with severe diseases.

Looking ahead to 2023 and beyond, we are confident in our ability to pave the way for future strong growth and value. We remain committed to creating value for patients in immunology, neurology, and other domains that align with the unmet needs of our stakeholders, now and into the future.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.

CAPTCHA
5 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.